Evaxion Biotech A/S (NASDAQ:EVAX) Shares Down 1%

Evaxion Biotech A/S (NASDAQ:EVAX)’s stock price fell 1% on Monday . The company traded as low as $3.87 and last traded at $3.91. 19,408 shares changed hands during trading, a decline of 96% from the average session volume of 495,976 shares. The stock had previously closed at $3.95.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the stock. LADENBURG THALM/SH SH upgraded shares of Evaxion Biotech A/S from a “neutral” rating to a “buy” rating and set a $8.00 target price for the company in a report on Tuesday, April 2nd. HC Wainwright reiterated a “buy” rating and issued a $14.00 price objective on shares of Evaxion Biotech A/S in a report on Wednesday, April 3rd.

Evaxion Biotech A/S Stock Down 1.0 %

The business’s fifty day moving average is $3.58 and its two-hundred day moving average is $5.80. The stock has a market cap of $20.39 million, a price-to-earnings ratio of -0.58 and a beta of -0.22.

Evaxion Biotech A/S (NASDAQ:EVAX) last posted its quarterly earnings results on Wednesday, March 27th. The company reported ($0.16) EPS for the quarter. The business had revenue of $0.07 million for the quarter. As a group, sell-side analysts expect that Evaxion Biotech A/S will post -0.19 earnings per share for the current year.

Institutional Investors Weigh In On Evaxion Biotech A/S

A hedge fund recently raised its stake in Evaxion Biotech A/S stock. Beacon Capital Management LLC boosted its position in Evaxion Biotech A/S (NASDAQ:EVAX) by 606.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 48,633 shares of the company’s stock after acquiring an additional 41,752 shares during the quarter. Beacon Capital Management LLC owned 0.17% of Evaxion Biotech A/S worth $33,000 at the end of the most recent quarter. Institutional investors and hedge funds own 11.04% of the company’s stock.

Evaxion Biotech A/S Company Profile

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase 1/2a trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy that is in pre-clinical stage for the treatment of various cancers.